Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Nataliia Kravchenko (Dniepropetrovsk, Ukraine), Nataliia Kravchenko, Tetyana Pertseva, Tetyana Kireeva. Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?. Eur Respir J 2015; 46: Suppl. 59, 708

Member's Comments

No comment yet.

Related content which might interest you: Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Biomarkers in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Biomarkers and community-adquired pneumonia (CAP) etiology Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 41s Year: 2007 Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65 Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018